Brooklyn ImmunoTherapeutics Inc (NYSE:BTX - Get Free Report) declared a dividend on Monday, March 3rd, NASDAQ Dividends reports. Investors of record on Friday, March 14th will be given a dividend of 0.0862 per share on Monday, March 31st. The ex-dividend date is Friday, March 14th.
Brooklyn ImmunoTherapeutics Stock Down 1.0 %
BTX stock traded down $0.07 during trading on Tuesday, hitting $6.90. The company had a trading volume of 880,933 shares, compared to its average volume of 816,089. The firm has a 50-day moving average price of $1.61 and a 200-day moving average price of $1.24. Brooklyn ImmunoTherapeutics has a 12 month low of $6.66 and a 12 month high of $8.31. The stock has a market cap of $405.90 million, a price-to-earnings ratio of -3.04 and a beta of 4.61.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics in a research report on Wednesday, February 26th. They set a "hold" rating for the company.
Read Our Latest Report on BTX
Brooklyn ImmunoTherapeutics Company Profile
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
